38 results about "Induction immunosuppression" patented technology

The invention discloses a combined preparation containing IL-10 and rapamycin, able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune responses mediated by T cells.

A method for preparing dendritic cells which have an enhanced potential to suppress immune responses, method for suppressing immune response by comprising administering them, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating or preventing various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells ensures the cells to be effectively used as an immunosuppressive agent.

Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.

The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in:i. the 1-19 amino acid sequence of sequence SEQ ID No. 3;ii. an amino acid sequence possessing (a) the substitution of at least one amino acid, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3 or (b) the deletion of at least four consecutive amino acids, compared to the 20-29 corresponding amino acid sequence of sequence SEQ ID No. 3; andiii. the 30-98 amino acid sequence of sequence SEQ ID No 3.

The invention provides a compound shown in the formula I in the specification and pharmaceutically acceptable salts of the compound, the preparation method of the compound and pharmaceutically acceptable salts of the compound and a medicine composition containing the compound shown in the formula I or the pharmaceutically acceptable salts of the compound. In the compound provided by the invention, each end group of the polyethylene glycol molecule is capable of bonding with a plurality of rapamycin molecules through cactus oligopeptide, and the medicine loading rate is improved. The compound can be used for inducing immunosuppression and treating transplant rejection, self-immune diseases, solid tumors, fungal infection and cardiovascular and cerebrovascular diseases.

The invention discloses a vaccine for treating and / or preventing type I diabetes and an application thereof. The active ingredients of the vaccine are as follows: 1) or 2) or 3): 1) proteantigen of type I diabetes and an immunosuppressor; 2) an epitope peptide of the proteantigen of type I diabetes and the immunosuppressor; and 3) the proteantigen of type I diabetes, the epitope peptide of the proteantigen of type I diabetes and the immunosuppressor, wherein the proteantigen of type I diabetes is at least one of insulin, glutamate decarboxylase and islet amyloid polypeptide; and the immunosuppressor is at least one of dexamethasone, cyclosporin A, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, early-group prednisolone, anti-CD4 monoclonal antibody and anti-C3 monoclonal antibody. The composition can promote Treg proliferation, accelerate secretion of IL-10 and TGF-beta, control the blood glucose level, inhibit the killing action of autoimmune responsive CD8 T cells, inhibit DC cell maturation, and induce immunosuppression so as to effectively treat type I diabetes.

An object of the present invention is to provide a drug and a method for effectively inducing donor-specific immune tolerance in a recipient in transplantation therapy. A complex of an siRNA for a costimulatory factor and schizophyllan is delivered to a Dectin-1 expressing cell which specifically recognizes schizophyllan to regulate the function of the Dectin-1 expressing cell, and therefore can induce immunosuppression effect as well as induce immune tolerance effectively.

This invention is concerned with a vaccine against dental caries obtained from the supernatant over cultures of the cariogenic bacteria Streptococcus sobrinus and S. mutans that consists of extracellular proteins. These proteins provide the suppression of the immune response in the host through the early production of IL-10, an anti-inflammatory cytokine and are, for that reason, virulent factors to the microorganism enhancing bacterial load in the host. These proteins were designated as virulence-associated immunomodulatory extracellular proteins (VIP). Vaccination through the host immunization with active VIP in a submitogenis dose, inactivated VIP or enolase in a dose unable to induce immunosuppression, induces the immunoneutralization of the VIP immunobiological effects.Vaccination can be used both as a preventive or therapeutic measure of dental caries as long as it is administered (intranasally, orally or subcutaneously) into mammals before or after bacterial infection, respectively.